During recent decades the importance of perceiving isolated systolic hypertension (ISH) in cardiovascular pathophysiology has been changed from a benign condition to the major cardiovascular risk factor. Aging is per se associated with the deterioration in arterial compliance through both structural and functional changes in large arteries which mainly involves the intima and media. The observed changes result in a decrease of the lumen-to-wall ratio, the overall lumen cross-sectional area and an increase of arterial stiffness which especially involve the aorta and other elastic arteries. In addition to the structural changes in vessel walls, aging is associated with certain functional changes such as an increase in sympathetic system activity probably due to the age-related decreased sensitivity of beta-receptors. While the function of arterial wall alpha-receptors remains intact, in elderly subjects a shift towards arterial vasoconstriction can be observed. 
Introduction
The long-term and cross-sectional studies performed in westernised populations demonstrated the presence of an age-dependent increase in both systolic and diastolic blood pressure (SBP/DBP) up to the 6th decade of life. 1, 2 However, in elderly subjects, DBP slowly decrease contrary to SBP. Only in specific populations, such as the inhabitants of New Guinea, Solomon's Islands or Brazilian Indians, no Correspondence: Dr Jó zef Kocemba, Department of Gerontology and Family Medicine, Wielicka 267, 30-663 Cracow, Poland but also cardiovascular morbidity. Risk of non-fatal stroke and myocardial infarction was increased three and two-times respectively in the presence of ISH.
Three major up-to-date studies that included patients with ISH have been published. In concordance to the previously published SHEP and MCR trials, the most recent, the Systolic Hypertension in the Elderly Trial (SYST-EUR), demonstrated that active treatment significantly reduces the risk of stroke and all fatal and non-fatal cardiac end-points, including sudden death. Of note, these benefits were demonstrated with new antihypertensive classes such as dihydropiridyne calcium channel blocker (nitrendipine) and the angiotensinconverting enzyme inhibitor (enalapril).
The necessity to carefully balance the benefits and risks of anti-hypertensive therapy in the elderly indicates that patients with suspected ISH should undergo careful BP measurements on at least three different occasions before the diagnosis is established and an orthostatic reaction should be evaluated.
If non-pharmacological procedures fail, drug therapy should be considered, especially in elderly patients with a SBP over 160 mm Hg, since their risk of complications is markedly higher. Pharmacological treatment should also be strongly considered in patients with a SBP between 140 and 160 mm Hg with such concomitant cardiovascular risk factors as diabetes, angina pectoris, and left ventricular hypertrophy. The drug regimen should be simple, starting with a low dose of a single drug that is titrated slowly. The selection of the first-line anti-hypertensive agent should be based on a careful assessment of pathophysiological and clinical parameters in each individual geriatric patient.
increase in BP is observed with age. 3 These populations are characterised by a low salt diet, high physical activity and a low prevalence of obesity and presumably these factors protect them from the detrimental changes in BP.
During recent decades the importance of perceiving isolated systolic hypertension (ISH) in cardiovascular pathophysiology has been changed from a benign condition to a major risk factor. 4, 5 Previously, only DBP was considered as a meaningful predictor of future cardiovascular events, and as a main goal of anti-hypertensive therapy. 6 Recently, the prospective as well as retrospective epidemiological studies have demonstrated that elevation of the systolic component of BP cannot be ignored even in the absence of high diastolic pressure. [7] [8] [9] [10] [11] [12] The fatal role of ISH depends on both its high prevalence in the elderly and pivotal influence on the cardiovascular system.
Pathophysiology of ISH
Changes in the mechanical properties of large vessels, such as a decrease in arterial compliance, are responsible for the increase in systolic with concomitant decrease in diastolic BP. [13] [14] [15] [16] [17] Concomitantly, the level of SBP is related to the maximal blood flow velocity in large arteries, which in the early phase of the cardiac cycle depends on heart and pulse wave velocity and in the later phase on the number of reflected waves. 16, 17 Pulse wave velocity is inversely related to the distensibility of large arteries which is responsible for the faster outflow of blood in diastole and results in the decrease in DBP.
Aging is per se associated with a deterioration in arterial compliance through both functional and structural changes in the large arteries which mainly involve the intima and media. [18] [19] [20] While aging, changes in collagen, ground substance, extracellular protein matrix, and cross-linkage occur, altering the anatomy and functional properties of the vasculature. 21 Arterial wall elastin decreases with age, resulting in thin elastic laminae and fragmented, poorly demarcated media. Calcium and lipids accumulate in blood vessel media and calcium binds to the altered elastin. Undifferentiated muscle cells migrate through the elastic laminae to the intima, proliferate, and produce connective tissue with thickening and fibrosis of the intima, which cause arterial wall thickness and stiffness. The amount of type III and type I collagen increases, produced by the phenotypically transformed smooth muscle cells that invade the intima. Contractility of these cells is partially lost, while synthetic activity is increased.
These changes result in a decrease of the lumento-wall ratio, the overall lumen cross-sectional area and an increase of arterial stiffness which especially involve the aorta and other elastic arteries. 22, 23 In addition to the structural changes in the vascular walls, aging is associated with certain functional changes such as increased sympathetic activity. 18 Higher levels of noradrenaline may be related to the baroreceptor dysfunction or lower sensitivity of beta-receptors. [24] [25] [26] Studies performed in the elderly show that they are characterised by decreased baroreceptor sensitivity to changes in BP. 27, 28 In younger subjects, an increase in BP is associated with a higher activity of baroreceptors and decreased sympathetic impulsation which results in lower levels of noradrenaline (NA). 29 It has been suggested that lower sensitivity of baroreceptors in the elderly might be secondary to the structural changes in carotid arteries and aorta and that it initiates the increase in sympathetic activity and higher levels of NA. 25, 28 Of note, this dysfunction of baroreceptors is probably responsible for higher variability of BP in the elderly resulting in orthostatic or postprandial BP falls. 30 The increased sympathetic activity in the elderly is probably also related to the age-related decreased sensitivity of beta-receptors. 31 While function of arterial wall alpha-receptors remains intact, 32 in the elderly subjects a shift towards arterial vasoconstriction can be observed.
The decrease in beta-receptor function manifests 21 by:
(1) lower maximal heart rate response to exercise; (2) lower plasma renin activity; (3) decreased relaxation of aorta after isoproterenol infusion; (4) decreased inotropic and batmotropic answer of the heart to catecholamines.
Although a number of beta-receptors remains unchanged they show lower affinity to agonists and post-receptor defect.
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Epidemiology
The analysis of various studies shows that assessment of the prevalence of ISH depends to a large extent on the number of BP measurements, the criterion of ISH diagnosis, age and gender of the population studied (Table 1) .
A recently published meta-analysis of larger trials shows that the prevalence of ISH has increased from 0.8% in subjects 50 years old, 5%-60 years old, 12.6%-70 years old, up to 23.6% in persons 80 years old. It was higher in women and black subjects when compared respectively with men and white subjects. 33 While treated subjects show a high prevalence of ISH it might be explained by either a tendency to treat DBP more aggressively, 'white coat effect', or more difficulties in lowering systolic than diastolic BP.
The introduction of 24-h non-invasive BP monitoring permitted easy and validated assessment of BP level and its variations during the day-and nighttime. [34] [35] [36] The 'white coat effect' can be easily detected as well as white coat hypertension. It has been shown that subjects with ISH are characterised by a higher variability of BP, high prevalence of white coat effect and postprandial fall. The question whether those with high office SBP and low SBP in the entire 24 h (white coat hypertensives) should be treated still remains disputable and further prospective studies are needed.
In most of the previously cited studies the definition of ISH was based on the criterion of 160/95 mm Hg or 160/90 mm Hg while in recognition of high risk associated with SBP the WHO/ISH guidelines 37 and the most recently published Report of the Sixth Joint National Committee on Hypertension 38 indicated that an ISH should be diagnosed when SBP is у140 mm Hg and DBP is Ͻ90 mm Hg. Thus the setting down of normal values of SBP will lead to earlier diagnosis and treatment of ISH.
Cardiovascular risk
The fatal role of systolic hypertension was shown for the first time in 1959 in the Build and Blood Pressure Study. The retrospective analysis of insurance company data demonstrated that the increase in total mortality was more closely related to higher systolic than diastolic BP and moreover, this effect was not age-dependent. 33 Subsequent prospective studies confirmed these early observations. In the US Hypertension Detection and Follow-up Programme the mortality rate among those with ISH was 17.6%, and 7.5% in subjects with a BP within normal limits. 39 Multiple regression analysis showed that 1 mm Hg increase in SBP was associated with a 1% increase in mortality. Similar results were observed in the Multiple Risk Factor Intervention Trial (MRFIT). 40 Subjects with a DBP between 75-79 mm Hg and SBP Ͼ160 mm Hg had a 2.6 higher risk of death than those with a SBP between 110-119 mm Hg. For any given level of DBP, an increase in SBP was associated with a similar increase in CV risk.
Data from the Framingham Study showed that ISH was associated not only with increased mortality but also cardiovascular morbidity. 4, 5 The risk of nonfatal stroke and myocardial infarction was increased three-and two-fold respectively in the presence of ISH.
Benefits of treatment
The data from the MRFIT have confirmed that in terms of estimating risk, increases in systolic pressure may be more important than in diastolic pressure. 41 Three major up-to-date studies that included patients with ISH have been published.
The Medical Research Council (MRC) trial of hypertension in the elderly included 4396 patients who were aged 65 to 74 years at the beginning of the trial. 9 Although the authors of the MRC included patients with a SBP 160-209 mm Hg and a DBP Ͻ115 mm Hg, the average BP at entry to the trial was 183/91 mm Hg, and 43% of the participants had a SBP у160 mm Hg and a DBP Ͻ90 mm Hg. The subjects were randomised to receive a diuretic-hydrochlorothiazide plus a potassium sparing agent, or a placebo, or atenolol (50 mg/day). The mean followup in the trial exceeded 5 years. Both active treatment regimens reduced BP to a greater extent than did the placebo. The average difference in BPs in the treated as compared to the placebo group was approximately −20/−10 mm Hg. More patients originally randomised to receive ␤-blockers required additional drugs than those randomised to receive diuretics (52% vs 38%). One hundred and seventyfive patients in the placebo group withdrew from the trial because of severely elevated BPs, as compared with only a few patients in the active treatment group. The actively treated subjects (diuretics or ␤-blockers) experienced 25% fewer strokes, a statistically significant reduction in all cardiovascular events, and 19% fewer coronary events (a statistically non-significant difference) than did the placebo group.
In 1984, after a successful pilot study, the National Heart, Lung and Blood Institute started recruitment for a Systolic Hypertension in the Elderly Program (SHEP) to determine whether antihypertensive drug treatment was effective in reducing the risk of stroke (fatal plus non-fatal) in a cohort of men and women у60 years with ISH. 10 A total of 4736 persons (43% men, 14% black) were recruited over a 3-year period and randomised to receive either a stepped anti-hypertensive regimen or matching placebo. At randomisation, the mean age was 72 years, the average BP was 170 mm Hg systolic, 77 mm Hg diastolic, and most subjects (90%) were free from previous episodes of cardiovascular disease, only 5% had a history of myocardial infarction, approximately 10% of the subjects had diabetes. Consequently, the subjects were a relatively healthy group of the elderly hypertensive patients. The subjects randomised to active treatment initially received chlorthalidone (12.5 mg/day) to reduce SBP below 160 mm Hg (in those whose SBP was initially above 180 mm Hg) and to produce a 20 mm Hg decrease in SBP in the remaining subjects. In those who were unable to achieve the BP goal, the treatment was increased initially to chlorthalidone 25 mg and subsequently with the addition of atenolol (25 or 50 mg/day); to those unable to tolerate atenolol, reserpine was given. During an average follow-up period of 4.5 years, SBP was (on average) 11-14 mm Hg lower and DBP was 3-4 mm Hg lower in the actively treated group. During this time, about 10% of the 'actively treated' group discontinued active treatment, whereas the percentage of those receiving placebo treatment who required an introduction of an active therapy increased progressively from 13% at year 1 to 44% at year 5. BP in almost 50% of actively treated participants was controlled with chlorthalidone alone. An active treatment produced a variety of side effects, and abnormal laboratory findings were more often than on placebo therapy. For example, problems specified as intolerable were reported by 38% of those taking active treatment but only 21% of those receiving placebo. The most important finding in the study was a 36% reduction in the incidence of stroke (P = 0.0003), which represented an absolute benefit of six events per 1000 patient years of treatment. On the other hand, the incidence of non-fatal myocardial infarction as well as the all-cause mortality were non-significantly lowered (respectively, by 27% and 13%). Also, an increase in non-vascular mortality was observed in those receiving the treatment, but this was small and not statistically significant (109 vs 103 deaths in the placebo group).
Therefore, the European Working Party on Hypertension in the Elderly, after considering all the results of the SHEP trial decided to continue the previously started Systolic Hypertension in the Elderly Trial (SYST-EUR). 12 Of 8926 screened patients, 6403 (71.7%) were eligible for enrolment in the run-in period, and 4695 were randomised. Initial average sitting BP (from three run-in visits) was 160-219 mm Hg with a diastolic pressure lower than 95 mm Hg. After stratification for centre, sex, and previous cardiovascular complications, the patients were randomly assigned to nitrendipine 10-40 mg daily, with a possible addition of enalapril 5-20 mg daily and hydrochlorothiazide 12.5-25 mg daily or matching placebo. In the two treatment groups combined, 1402 (29.9%) patients had cardiovascular complications at randomisation; 575 (41.0%) and 103 (7.3%) of these patients had symptoms and signs suggestive of coronary heart disease, respectively. At a median of 2 years follow-up, sitting systolic and diastolic BPs had fallen by 13 mm Hg and 2 mm Hg in the placebo group (n = 2297) and by 23 mm Hg and 7 mm Hg in the active treatment group (n = 2398). The between-group differences were systolic 10.1 mm Hg, and diastolic 4.5 mm Hg. Uncontrolled hypertension led 5.5% patients in the placebo group and 0.5% patients in the active treatment group to withdraw from treatment. Active treatment reduced the total rate of stroke from 13.7 to 7.9 endpoints per 1000 patient-years (42% reduction, P = 0.003). Non-fatal stroke decreased by 44% (P = 0.007). In the active treatment group, all fatal and non-fatal cardiac end-points, including sudden death, declined by 26% (P = 0.03). Non-fatal cardiac end-points decreased by 33% (P = 0.03) and all fatal and non-fatal cardiovascular end-points decreased by 31% (P Ͻ 0.001). Cardiovascular mortality was slightly lower on active treatment (−27%, P = 0.07), but all-cause mortality was not affected (−14%, P = 0.22). The end-points decreased similarly in east and west European patients.
Practical considerations
The necessity to carefully balance the benefits and risks of anti-hypertensive therapy in the elderly indicates that patients with suspected ISH should undergo BP measurements on at least three different occasions before the diagnosis is established and an orthostatic reaction should be evaluated. 13 Moreover, less frequent but potentially curable secondary causes of ISH such as aortic insufficiency, atrioventricular fistula, thyreotoxycosis, Paget's disease of the bone, beriberi, and severe anaemia should be eliminated. Also the presence of 'pseudohypertension', in which the rigidity of arterial vessels produces falsely high BP readings, although uncommon, should be suspected, especially in patients with severe ISH without signs of end-organ damage. 41 In addition, elderly persons with hypertension, especially women, may have 'white-coat hypertension' and excessive variability in SBP, and in such cases home BP readings or 24-h ambulatory BP monitoring should be considered. 34, 35 Once the diagnosis of ISH is firmly established, therapeutic interventions should begin.
In most elderly patients with stage 1 and stage 2 systolic hypertension non-pharmacological treatment can be prescribed as empirical therapy. Lifestyle modifications including weight reduction, increased physical activity, moderation of dietary sodium, and decreased alcohol intake, either alone or in combination with pharmacological therapy, may in some elderly patients effectively reduce BP.
If non-pharmacological procedures fail, drug therapy should be considered, especially in elderly patients with a SBP Ͼ160 mm Hg, since their risk of complications is markedly higher. 13, 42 Pharmacological treatment should also be taken into account in patients with a SBP between 140 and 160 mm Hg with such concomitant cardiovascular risk factors as diabetes, angina pectoris, and left ventricular hypertrophy. 38 The drug regimen should be simple, starting with a low dose (about half of that used in younger patients) of a single drug that is titrated slowly, if necessary, until a SBP Ͻ140 mm Hg is attained. Such an approach will minimise the possibility of orthostatic hypotension and undue lowering of DBP. The exaggerated reduction in DBP may compromise coronary perfusion in elderly hypertensive patients, in whom the coronary arteries are frequently narrowed by obstructive atherosclerotic lesions, and in whom a hypertrophied ventricle may pose higher demands on the supply of oxygen and nutrients. 43 Systolic pressure in elderly patients with ISH can be specifically lowered by actively increasing arterial compliance, by reducing the forward pulse velocity during ventricular ejection, and by altering the timing during systole of the reflected pressure waves. 17 Vasoactive drugs that reduce smooth muscle tone in the large arteries actively increase arterial compliance. 44 This effect has been demonstrated for calcium antagonists, 45 angiotensin-converting enzyme (ACE) inhibitors, 46 nitrates, 47 and ␤-blockers with intrinsic sympathomimetic activity, such as pindolol. 44 In contrast, propranolol, hydralazine, 44 and some postsynaptic ␣-adrenergic blockers 48 do not actively increase arterial compliance. Calcium antagonists and ACE inhibitors have also been shown to decrease pulse wave velocity, 44 and nitrates 49 to delay reflected pressure waves by dilating peripheral arteries more than thoracic aorta. 44 Systolic pressure can also be lowered in patients with ISH by decreasing the blood volume ejected from the left ventricle during each heart cycle, as observed when ventricular pacing is accelerated. 44 Diuretics decrease both plasma and stroke volume and this may explain their efficacy in reducing SBP in patients with ISH. 44 The selection of the first-line anti-hypertensive agent should also be based on a careful assessment of pathophysiological and clinical parameters in the geriatric population. 43 Table 2 briefly outlines the properties of various anti-hypertensive classes.
